FacebookTwitterGoogle+RedditEmail

Has the Drug Industry’s Grip On Health Care Become a Pharmageddon?

David Healy is a Professor of Psychiatry at Bangor University. He is a former Secretary of the British Association for Psychopharmacology, and author of over 175 peer reviewed articles, 200 other pieces and 20 books, including The Antidepressant Era, and The Creation of Psychopharmacology from Harvard University Press, The Psychopharmacologists Volumes 1-3, Let Them Eat Prozac, Mania, & Pharmageddon.  He has been involved as an expert witness in homicide, suicide and birth defect legal actions involving psychotropic drugs, and in bringing problems with these drugs to the attention of American and British regulators, as well raising awareness of how pharmaceutical companies sell drugs by marketing diseases and co-opting academic opinion-leaders, ghostwriting their articles.

Rosenberg: Your new book, Pharmageddon, gives a bleak picture of the doctored data, skewed drug trials and rigged treatment guidelines that characterize today’s pharmaceutical industry. Many people will be shocked to learn the abuses are not limited to the US, where direct-to-consumer advertising is legal, but found in Europe. 

Healy: The situation is identical. Pharma actually finds socialized health care systems easier to exploit. And despite direct-to-consumer advertising, more money is spent on marketing to doctors who are the real consumers. They are also pressured by the treatment guidelines process which is based on “evidence” that Pharma makes sure to keep secret so they are really in the dark, though they may not realize it.

Rosenberg: One example you give of Pharma’s reach and power is the eerie symmetry between the Texas Medication Algorithm Project (TMAP), conceptualized and funded by US Pharma, and Britain’s National Institute for Health and Clinical Excellence (NICE).

Healy: Despite their public/private differences, both organizations recommend the use of branded antipsychotics like Risperdal, Zyprexa and Seroquel before the use of older, affordable antipsychotics which of course enriches Pharma. One of the other issues is this–there is a new bill aimed at speeding up the FDA approval process yet again–and also getting regulators to take into account the jobs that come with a strong pharmaceutical sector.  Both America and Europe have been keen to keep their companies happy and have turned a blind eye to the outsourcing of clinical trials to Asia and Eastern Europe.

Rosenberg: In Pharmageddon, you chronicle how clinical trial oversight has gone from a hospital and university-based system to a for-profit system run by clinical research organizations or CROs.

Healy: The drug companies have outsourced all their operations from drug development and testing to clinical trials to scientific and academic writing so that they have become nothing but marketing organizations at their core. At each juncture where they have spun off a traditional responsibility, no one has objected and so it continues.

Rosenberg: There have been reports of risks to human subjects in overseas trials as well as bribes and protocol irregularities. Who oversees the ethics of outsourced trials and the quality of their data?

Healy: Clinical trials are overseen by private Institutional Review Boards, which are funded by the organizations they regulate–

Rosenberg: Like Moody’s and Standard & Poor’s are funded by their clients? 

Healy: Yes. A recent large trial for the antipsychotic Abilify demonstrates the danger with outsourced clinical trials. On the basis of about 28 trials in the US, Abilify did not prophylactically stabilize mood as the manufacturer wants to claim. But when data from just two trials from Mexico were mixed in, it did.

Rosenberg: Most of Pharma’s power to mislead and harm comes from such opaque and distorted data, you charge in Pharmageddon.

Healy: Without access to the raw drug data, medical professionals cannot practice responsible medicine and guidelines cannot be written. Yet Pharma, with very few exceptions, refuses to publish the data and share them with practitioners. This result is guidelines that are fictions and doctors who lack critical information they need to prescribe and treat.

Rosenberg: Pharma’s stonewalling of data and use of ghostwriters has resulted in articles in major medical journals that made Vioxx,  hormone therapy and Neurontin look safe when they weren’t. Another example you give is a paper in the Journal of the American Association of Child and Adolescent Psychiatry in which GlaxoSmithKline (GSK) has made the antidepressant Paxil look safe by hiding raw data. Then editor, Mina Dulcan, says about the missing data, which hid Paxil’s suicidal side effect in children, “I can’t control the authors. No, I don’t have regrets.”

Healy: If we were getting our drug information from the New York Times instead of medical journals, we would all be a lot safer. When the Times reporter Jayson Blair was found to have fabricated stories, he was history. But the editors and writers involved with journal fraud still have their jobs and the articles are not even retracted. In fact, Liz Wager, the chair of the Committee on Publication Ethics (COPE) is herself Pharma linked.

[Ed note. The COPE site says, “Liz provides writing, editing, training and consultancy services for various pharmaceutical companies (most recently Astra Zeneca, Cephalon, Cordis, GlaxoSmithKline, Eli Lilly, Janssen-Cilag, Merck Serono, Mundipharma, Norgine, Novo Nordisk, Sanofi Pasteur and Vifor). ]

Rosenberg: Many conflicts of interest in your book, including COPE’s leadership, are structural and create a closed loop of misinformation, especially because of the money that Pharma wields. How can sunlight and transparency ever break through?

Healy: Some colleagues and I are in the process of fine-tuning a free web site that offers FDA MedWatch data with other crucial dug information but gets people affected by treatment to report in detail for perhaps the first time. The site, called RxISK.org, also helps patients file an adverse event report to US and Canadian authorities, with other countries to follow. For too long, patients, doctors and pharmacists have been isolated  from each other when they encounter adverse drug events and only Pharma’s messages get out. This will help them communicate directly.

Martha Rosenberg’s is an investigative health reporter. Her first book,  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health, has just been released by Prometheus books.


More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

Weekend Edition
February 22, 2019
Friday - Sunday
Timothy M. Gill
Why is the Venezuelan Government Rejecting U.S. Food Supplies?
John Pilger
The War on Venezuela is Built on Lies
Andrew Levine
Ilhan Omar Owes No Apologies, Apologies Are Owed Her
Jeffrey St. Clair
That Magic Feeling: the Strange Mystique of Bernie Sanders
David Rosen
Will Venezuela Crisis Split Democrats?
Jeffrey St. Clair - Joshua Frank
Curtain Call: A Response to Edward Curtin
Nick Pemberton
Donald Trump’s National Emergency Is The Exact Same As Barack Obama’s National Emergency
Paul Street
Buried Alive: The Story of Chicago Police State Racism
Rob Seimetz
Imagined Communities and Omitting Carbon Emissions: Shifting the Discussion On Climate Change
Ramzy Baroud
Russian Mediation: The Critical Messages of the Hamas-Fatah Talks in Moscow
Michael Welton
Dreaming Their Sweet Dreams: a Peace to End Peace
Robert Hunziker
Global Warming’s Monster Awakens
Huma Yasin
Chris Christie Spins a Story, Once Again
Ron Jacobs
Twenty-First Century Indian Wars
Robert Fantina
The U.S. and Venezuela: a Long History of Hostility
Lance Olsen
Climate and Money: a Tale of Two Accounts
Louis Proyect
El Chapo and the Path Taken
Fred Gardner
The Rise of Kamala Harris
John W. Whitehead
Rule by Fiat: National Crises, Fake Emergencies and Other Dangerous Presidential Powers
Kollibri terre Sonnenblume
Biomass is Not “Green”: an Interview With Josh Schlossberg
John Feffer
Answering Attacks on the Green New Deal
W. T. Whitney
US Racism and Imperialism Fuel Turbulence in Haiti
Kim Ives
How Trump’s Attacks on Venezuela Sparked a Revolution in Haiti
Mike Ferner
What War Films Never Show You
Lawrence Wittner
Should the U.S. Government Abide by the International Law It Has Created and Claims to Uphold?
James Graham
A Slow Motion Striptease in France
Dave Lindorff
Could Sanders 2.0 Win It All, Getting the Democratic Nomination and Defeating Trump?
Jill Richardson
Take It From Me, Addiction Doesn’t Start at the Border
Yves Engler
Canada and the Venezuela Coup Attempt
Tracey L. Rogers
We Need a New Standard for When Politicians Should Step Down
Gary Leupp
The Sounds of Silence
Dan Bacher
Appeals Court Rejects Big Oil’s Lawsuit Against L.A. Youth Groups, City of Los Angeles
Robert Koehler
Are You White, Black or Human?
Ralph Nader
What are Torts? They’re Everywhere!
Sarah Schulz
Immigrants Aren’t the Emergency, Naked Capitalism Is
James Campbell
In the Arctic Refuge, a Life Force Hangs in the Balance
Matthew Stevenson
Pacific Odyssey: Corregidor’s Iconography of Empire
Jonah Raskin
The Muckraking Novelist Dashiell Hammett: A Red Literary Harvest
Kim C. Domenico
Revolutionary Art and the Redemption of the Local
Paul Buhle
Life and Crime in Blue Collar Rhode Island
Eugene Schulman
J’Accuse!
Nicky Reid
Zionists are the Most Precious Snowflakes
Jim Goodman
The Green New Deal Outlines the Change Society Needs
David Yearsley
The Political Lyre
Cesar Chelala
The Blue Angel and JFK: One Night in Camelot
FacebookTwitterGoogle+RedditEmail